Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
This trial tests a new treatment called retatrutide (a GLP-1/GIP/glucagon tri-agonist) to assess its effects on kidney function in individuals who are overweight or have obesity and chronic kidney disease
[additionals]
In this 72-week trial TZP 10 mg and 15 mg determinate a clinically meaningful reduction in BW, with a safety profile comparable to GLP1-RA- based therapies (104)
The SURMOUNT-4 trial assessed the weight maintenance with tirzepatide and had also two periods: a 36-week open-label lead-in period during which all participants took tirzepatide, followed by a 52-week double-blind treatment period during which participants were randomised to either continue on tirzepatide or switch to placebo
US$ 28.37
US$ 26.66
US$ 24.99
US$ 23.55
US$ 29.43
US$ 20.11
US$ 29.95
US$ 23.18
US$ 22.10
US$ 21.74
US$ 24.68
